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Dynamics of interactions between the drugs caffeine 
and ciprofloxacin are predicted using 
physiologically-based pharmacokinetic (PBPK) 
modeling. Pharmacokinetic means the model 
determines where the drugs are distributed in the 
body over time. Physiologically-based means the 
anatomy and physiology of the human body is 
reflected in the structure and functioning of the 
model. Multiple drugs can interact to increase or 
decrease their beneficial and/or undesired effects. 
This is important because some common substances, 
such as caffeine in coffee and soft drinks, are actually 
drugs that affect the body. By implementing the 
model as a computer program, it is relatively 
straightforward to perform “experiments” that would 
be too costly, time-consuming, or even unethical, if 
done on humans.
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Drugs included in the model
Caffeine is a common 
psychoactive stimulant found in 
coffee, tea, soft drinks, and 
energy drinks.  Ciprofloxacin 
slows the rate at which the body 
eliminates caffeine.1
Ciprofloxacin is an antimicrobial 
used to treat bacterial infections 
by inhibiting DNA and protein 
synthesis.2 It is also used by the 
military to protect against 
anthrax, a biological weapon.
What is a model?
• A model is a representation of something.
• A model is designed for a purpose.
• The model abstracts details that are not 
important for its purpose.
• The model retains, exaggerates, or adds 
details that are important for its purpose.
• There are usually many different ways
to model something.
• A map and a globe are models of the Earth.
• The map adds colors to show different 
countries.
• The globe exaggerates height to emphasize 
mountains.
• Neither is the same size as the Earth.
• A map is easy to carry and can be scaled for 
different purposes.
• A globe can illustrate seasons, day and 
night, and great circle routes.
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Physiologically-based pharmacokinetic (PBPK) modeling3
• The block diagram (middle) is an 
example of how a human (left) can be 
modeled.
• Organs important for the drugs under 
study appear as compartments (blocks) 
connected by blood flow (arrows).
• Features not important for the drugs 
under study are omitted or combined 
into other (e.g., there is no brain).
• The model is described using 
mathematics (differential equations4).
Drugs enter or leave the body:
• Drugs can enter through various portals 
including intravenous or oral routes.
• Drugs circulate through the body via 
blood flow, or accumulate in tissue.
• Drugs are eliminated by the kidney 
(urine), the liver (metabolism), or the 
lungs.
• Metabolism breaks down drugs using 
enzymes (see example at right).
Example human 
(Charles Darwin)
Example metabolic pathways 
(caffeine metabolism)Example PBPK model
Results
• A PBPK model was implemented for caffeine and ciprofloxacin 
using the Mathematica program.
• Figures 1 and 2 show the concentrations of the drugs in each of the 
compartments of the model. The different characteristics of each 
compartment result in different drug concentrations.
Figure 1: Concentration of caffeine in the model compartments. Initial caffeine dose: 
100 mg.
Figure 2: Concentration of ciprofloxacin in the model compartments. Initial 
ciprofloxacin dose: 750 mg. 
Figure 3: Concentration of caffeine in the liver under different inhibition scenarios. 
Initial caffeine dose: 100 mg. Initial ciprofloxacin dose: 750 mg. 
• Ciprofloxacin inhibits the CYP1A2 enzyme.
• A model parameter KI is the dissociation constant of the enzyme-
inhibitor complex. A paper by Fuhr et al. provides a value for KI for 
ciprofloxacin and CYP1A2: 0.18 mM.5
• A paper by Healy et al. gives the results of an experiment where 
patients were given both caffeine and ciprofloxicin.1
• Figure 3 shows that when both drugs are present (blue, green), the 
level of caffeine is higher than for caffeine alone (black) because 
ciprofloxacin inhibits CYP1A2 from metabolizing caffeine.
• When Fuhr’s value for KI is used in the model (blue), the value for 
t1/2 for caffeine, the time for the caffeine concentration to reach half 
the original dose, does not match Healy’s experimental results.
• The PBPK model predicts a value of 7.5 μM for KI based on Healy’s 
experiment (green).
